



## **EYETECH VISION DAY TO PREVIEW FUTURE OF MACUGEN FRANCHISE**

**TOP EYETECH EXECUTIVES AND OPHTHALMOLOGY RESEARCHERS TO  
PRESENT AT EVENT THIS WEDNESDAY, JUNE 22, AT 11:45 A.M.**

- WHEN:** **Wednesday, June 22**  
**NEW time: 11:45 a.m. to 2:30 p.m. Eastern time\***  
\*Please join us for lunch at 11:45 a.m.  
Presentations will begin promptly at 12:15 p.m.
- WHERE:** **The Westin New York Hotel at Times Square**  
270 West 43<sup>rd</sup> Street (at 8<sup>th</sup> Avenue), New York City  
Broadway Ballroom (third floor)
- WHAT:** **Eyetech Pharmaceuticals**, makers of **Macugen<sup>®</sup>** (pegaptanib sodium injection) – the first anti-VEGF therapy indicated for the treatment of all subtypes of neovascular AMD – will present details about the Macugen franchise and novel therapies in the pipeline.
- WHO:** Information will be presented by top scientific researchers and senior corporate executives, including:
- Anthony P. Adamis, M.D., Executive Vice President of Research and Development and Chief Scientific Officer of Eyetech
  - Donald D’Amico, M.D., Professor of Ophthalmology at the Massachusetts Eye and Ear Infirmary at Harvard Medical School, and a member of the Eyetech Scientific Advisory Board
  - Errol De Souza, Ph.D., President and Chief Executive Officer of Archemix Corp.
  - David R. Guyer, M.D., Chief Executive Officer of Eyetech
  - Donald McDonald, M.D., Ph.D., Professor of Anatomy, University of California at San Francisco Comprehensive Cancer Center
  - David Shima, Ph.D., Senior Vice President of Research and Preclinical Development at Eyetech

If you are unable to attend in person, you can access a live audio Web cast of the presentation by logging on to the Investor Relations section at [www.eyetech.com](http://www.eyetech.com), or hear the audio portion of the Web cast by dialing 888-275-0218 (in the United States) or 706-679-7756 (internationally).

**CONTACTS:** Susan Silao, Eyetech  
212-824-3175  
[susan.silao@eyetech.com](mailto:susan.silao@eyetech.com)

Shelly Nelson, Edelman  
212-819-4845  
[shelly.nelson@edelman.com](mailto:shelly.nelson@edelman.com)

###